During this national emergency, the Diversion Control Division will continue to work with our federal partners, DEA registrants, and their representative association to assure that there is an adequate supply of controlled substances in the United States. The DEA will also work to assure that patients will have access to controlled substances.On March 16, 2020, the DEA published COVID-19 INFORMATION PAGE on the DIVERSION CONTROL DIVISIONS website. This page contains important guidance concerning COVID-19 and the national drug supply, electronic prescribing of controlled substances, telemedicine, medicated assisted treatment, and other important federal and state information. The site will be updated frequently as new information and guidance is issued. Please check back frequently for further information. Please continue to direct all policy questions concerning COVID-19 to the Policy email box at Natural.Disaster@usdoj.gov.
DEA UPDATE: Effective March 23, 2020, the DEA Call Center has TEMPORARILY suspended phone operations due to the COVID-19 health epidemic. Assistance will only be available through DEA.Registration.Help@usdoj.gov. DEA will respond to emails as quickly as possible.